T1	AdverseReaction 94 108	skin reactions
T2	AdverseReaction 88 93	fatal
T3	Severity 47 53	Severe
T4	AdverseReaction 152 176	Stevens-Johnson syndrome
T5	Severity 67 83	life threatening
T6	AdverseReaction 178 203	hypersensitivity reaction
T7	AdverseReaction 205 231	toxic epidermal necrolysis
T8	AdverseReaction 236 255	erythema multiforme
T9	Severity 545 551	Severe
T10	Severity 565 581	life-threatening
T11	AdverseReaction 587 592	fatal
T12	AdverseReaction 593 607	skin reactions
T13	AdverseReaction 651 675	Stevens-Johnson syndrome
T14	AdverseReaction 677 703	toxic epidermal necrolysis
T15	AdverseReaction 708 727	erythema multiforme
T16	AdverseReaction 729 755	Hypersensitivity reactions
T17	AdverseReaction 766 815	Drug Rash with Eosinophilia and Systemic Symptoms
T18	AdverseReaction 817 822	DRESS
T19	AdverseReaction 874 878	rash
T20	AdverseReaction 919 936	organ dysfunction
T21	AdverseReaction 948 963	hepatic failure
T22	AdverseReaction 1007 1013	rashes
T24	AdverseReaction 1221 1225	rash
T25	AdverseReaction 1261 1265	Rash
T26	AdverseReaction 1343 1347	rash
T27	AdverseReaction 2001 2015;2029 2040	Redistribution of body fat
T28	AdverseReaction 2016 2040	accumulation of body fat
T29	AdverseReaction 2052 2067	central obesity
T30	AdverseReaction 2069 2098	dorsocervical fat enlargement
T31	AdverseReaction 2100 2112	buffalo hump
T32	AdverseReaction 2032 2040;2115 2133	body fat peripheral wasting
T33	AdverseReaction 2135 2149	facial wasting
T34	AdverseReaction 2151 2169	breast enlargement
T35	AdverseReaction 2176 2197	cushingoid appearance
T36	AdverseReaction 2439 2469	Immune reconstitution syndrome
T37	AdverseReaction 2696 2717	inflammatory response
T38	AdverseReaction 2742 2766	opportunistic infections
T39	AdverseReaction 2776 2806	Mycobacterium avium  infection
T40	AdverseReaction 2808 2823	cytomegalovirus
T41	AdverseReaction 2826 2857	neumocystis jiroveci  pneumonia
T42	AdverseReaction 2859 2862	PCP
T43	AdverseReaction 2867 2879	tuberculosis
T44	AdverseReaction 2942 2962	Autoimmune disorders
T45	AdverseReaction 2972 2987	Graves' disease
T46	AdverseReaction 2989 3001	polymyositis
T47	AdverseReaction 3007 3030	Guillain-Barre syndrome
T48	Factor 553 564	potentially
T49	Severity 993 1000	Grade 3
T50	Severity 1005 1006;993 998	4 Grade
T23	DrugClass 2525 2539	antiretroviral
E1	AdverseReaction:T1 Effect:E3 Effect2:E5
E2	AdverseReaction:T2
E3	Severity:T3
E4	AdverseReaction:T4
E5	Severity:T5
E6	AdverseReaction:T6
E7	AdverseReaction:T7
E8	AdverseReaction:T8
E9	Severity:T9
E10	Severity:T10
E11	AdverseReaction:T11
E12	AdverseReaction:T12 Effect:E9 Effect2:E10 Hypothetical:E48
E13	AdverseReaction:T13
E14	AdverseReaction:T14
E15	AdverseReaction:T15
E16	AdverseReaction:T16
E17	AdverseReaction:T17
E18	AdverseReaction:T18
E19	AdverseReaction:T19
E20	AdverseReaction:T20
E21	AdverseReaction:T21
E22	AdverseReaction:T22 Effect:E50 Effect2:E49
E24	AdverseReaction:T24
E25	AdverseReaction:T25
E26	AdverseReaction:T26
E27	AdverseReaction:T27
E28	AdverseReaction:T28
E29	AdverseReaction:T29
E30	AdverseReaction:T30
E31	AdverseReaction:T31
E32	AdverseReaction:T32
E33	AdverseReaction:T33
E34	AdverseReaction:T34
E35	AdverseReaction:T35
E36	AdverseReaction:T36 Hypothetical:E23
E37	AdverseReaction:T37
E38	AdverseReaction:T38
E39	AdverseReaction:T39
E40	AdverseReaction:T40
E41	AdverseReaction:T41
E42	AdverseReaction:T42
E43	AdverseReaction:T43
E44	AdverseReaction:T44
E45	AdverseReaction:T45
E46	AdverseReaction:T46
E47	AdverseReaction:T47
E48	Factor:T48
E49	Severity:T49
E50	Severity:T50
E23	DrugClass:T23
A1	CUI E1 C0221743
A2	UMLS-Preferred-Name E1 Skin reaction
A3	MEDDRA-PT E1 Skin reaction
A4	MEDDRA-PT-ID E1 10040914
A5	CUI E2 C1306577
A6	UMLS-Preferred-Name E2 Death (finding)
A7	MEDDRA-PT E2 Death
A8	MEDDRA-PT-ID E2 10011906
A9	CUI E4 C0038325
A10	UMLS-Preferred-Name E4 Stevens-Johnson Syndrome
A11	MEDDRA-PT E4 Stevens-Johnson syndrome
A12	MEDDRA-PT-ID E4 10042033
A13	CUI E6 C0020517
A14	UMLS-Preferred-Name E6 Hypersensitivity
A15	MEDDRA-PT E6 Hypersensitivity
A16	MEDDRA-PT-ID E6 10020751
A17	LLT E6 Hypersensitivity reaction
A18	LLT-ID E6 10020756
A19	CUI E7 C0014518
A20	UMLS-Preferred-Name E7 Toxic Epidermal Necrolysis
A21	MEDDRA-PT E7 Toxic epidermal necrolysis
A22	MEDDRA-PT-ID E7 10044223
A23	CUI E8 C0014742
A24	UMLS-Preferred-Name E8 Erythema Multiforme
A25	MEDDRA-PT E8 Erythema multiforme
A26	MEDDRA-PT-ID E8 10015218
A27	CUI E11 C1306577
A28	UMLS-Preferred-Name E11 Death (finding)
A29	MEDDRA-PT E11 Death
A30	MEDDRA-PT-ID E11 10011906
A31	CUI E12 C0221743
A32	UMLS-Preferred-Name E12 Skin reaction
A33	MEDDRA-PT E12 Skin reaction
A34	MEDDRA-PT-ID E12 10040914
A35	CUI E13 C0038325
A36	UMLS-Preferred-Name E13 Stevens-Johnson Syndrome
A37	MEDDRA-PT E13 Stevens-Johnson syndrome
A38	MEDDRA-PT-ID E13 10042033
A39	CUI E14 C0014518
A40	UMLS-Preferred-Name E14 Toxic Epidermal Necrolysis
A41	MEDDRA-PT E14 Toxic epidermal necrolysis
A42	MEDDRA-PT-ID E14 10044223
A43	CUI E15 C0014742
A44	UMLS-Preferred-Name E15 Erythema Multiforme
A45	MEDDRA-PT E15 Erythema multiforme
A46	MEDDRA-PT-ID E15 10015218
A47	CUI E16 C0020517
A48	UMLS-Preferred-Name E16 Hypersensitivity
A49	MEDDRA-PT E16 Hypersensitivity
A50	MEDDRA-PT-ID E16 10020751
A51	LLT E16 Hypersensitivity reaction
A52	LLT-ID E16 10020756
A53	CUI E17 C3541994
A54	UMLS-Preferred-Name E17 Drug Hypersensitivity Syndrome
A55	MEDDRA-PT E17 Drug reaction with eosinophilia and systemic symptoms
A56	MEDDRA-PT-ID E17 10073508
A57	LLT E17 Drug rash with eosinophilia and systemic symptoms
A58	LLT-ID E17 10058919
A59	CUI E18 C3541994
A60	UMLS-Preferred-Name E18 Drug Hypersensitivity Syndrome
A61	MEDDRA-PT E18 Drug reaction with eosinophilia and systemic symptoms
A62	MEDDRA-PT-ID E18 10073508
A63	LLT E18 DRESS syndrome
A64	LLT-ID E18 10058899
A65	CUI E19 C0015230
A66	UMLS-Preferred-Name E19 Exanthema
A67	MEDDRA-PT E19 Rash
A68	MEDDRA-PT-ID E19 10037844
A69	CUI E20 C0349410
A70	UMLS-Preferred-Name E20 Single organ dysfunction
A71	MEDDRA-PT E20 Organ failure
A72	MEDDRA-PT-ID E20 10053159
A73	CUI E21 C0085605
A74	UMLS-Preferred-Name E21 Liver Failure
A75	MEDDRA-PT E21 Hepatic failure
A76	MEDDRA-PT-ID E21 10019663
A77	CUI E22 C0015230
A78	UMLS-Preferred-Name E22 Exanthema
A79	MEDDRA-PT E22 Rash
A80	MEDDRA-PT-ID E22 10037844
A81	CUI E24 C0015230
A82	UMLS-Preferred-Name E24 Exanthema
A83	MEDDRA-PT E24 Rash
A84	MEDDRA-PT-ID E24 10037844
A85	CUI E25 C0015230
A86	UMLS-Preferred-Name E25 Exanthema
A87	MEDDRA-PT E25 Rash
A88	MEDDRA-PT-ID E25 10037844
A89	CUI E26 C0015230
A90	UMLS-Preferred-Name E26 Exanthema
A91	MEDDRA-PT E26 Rash
A92	MEDDRA-PT-ID E26 10037844
A93	CUI E27 C0856151
A94	UMLS-Preferred-Name E27 Fat redistribution
A95	MEDDRA-PT E27 Fat redistribution
A96	MEDDRA-PT-ID E27 10048474
A97	CUI E28 C1096393
A98	UMLS-Preferred-Name E28 Body fat disorder
A99	MEDDRA-PT E28 Body fat disorder
A100	MEDDRA-PT-ID E28 10055164
A101	CUI E29 C0311277
A102	UMLS-Preferred-Name E29 Obesity, Abdominal
A103	MEDDRA-PT E29 Central obesity
A104	MEDDRA-PT-ID E29 10065941
A105	CUI E30 C0520573
A106	UMLS-Preferred-Name E30 Buffalo hump
A107	MEDDRA-PT E30 Lipohypertrophy
A108	MEDDRA-PT-ID E30 10062315
A109	LLT E30 Buffalo hump
A110	LLT-ID E30 10006539
A111	CUI E31 C0520573
A112	UMLS-Preferred-Name E31 Buffalo hump
A113	MEDDRA-PT E31 Lipohypertrophy
A114	MEDDRA-PT-ID E31 10062315
A115	LLT E31 Buffalo hump
A116	LLT-ID E31 10006539
A117	CUI E32 C0333650
A118	UMLS-Preferred-Name E32 Adipose Tissue Atrophy
A119	MEDDRA-PT E32 Lipoatrophy
A120	MEDDRA-PT-ID E32 10024604
A121	LLT E32 Fat atrophy NOS
A122	LLT-ID E32 10016242
A123	CUI E33 C1112303
A124	UMLS-Preferred-Name E33 Facial wasting
A125	MEDDRA-PT E33 Facial wasting
A126	MEDDRA-PT-ID E33 10056866
A127	CUI E34 C2225524
A128	UMLS-Preferred-Name E34 Macromastia
A129	MEDDRA-PT E34 Breast enlargement
A130	MEDDRA-PT-ID E34 10006242
A131	CUI E35 C0742929
A132	UMLS-Preferred-Name E35 CUSHINGOID APPEARANCE
A133	MEDDRA-PT E35 Cushingoid
A134	MEDDRA-PT-ID E35 10011655
A135	LLT E35 Cushingoid facies
A136	LLT-ID E35 10011656
A137	CUI E36 C1096197
A138	UMLS-Preferred-Name E36 Immune reconstitution syndrome
A139	MEDDRA-PT E36 Immune reconstitution inflammatory syndrome
A140	MEDDRA-PT-ID E36 10065042
A141	LLT E36 Immune reconstitution syndrome
A142	LLT-ID E36 10054014
A143	CUI E37 C1155266
A144	UMLS-Preferred-Name E37 inflammatory response
A145	MEDDRA-PT E37 Inflammation
A146	MEDDRA-PT-ID E37 10061218
A147	LLT E37 Inflammatory reaction
A148	LLT-ID E37 10021995
A149	CUI E38 C0029118
A150	UMLS-Preferred-Name E38 Opportunistic Infections
A151	MEDDRA-PT E38 Opportunistic infection
A152	MEDDRA-PT-ID E38 10030901
A153	CUI E39 C1411980
A154	UMLS-Preferred-Name E39 Mycobacterium avium infection
A155	MEDDRA-PT E39 Mycobacterium avium complex infection
A156	MEDDRA-PT-ID E39 10058806
A157	LLT E39 Infection mycobacterium avium
A158	LLT-ID E39 10021840
A159	CUI E40 C0010823
A160	UMLS-Preferred-Name E40 Cytomegalovirus Infections
A161	MEDDRA-PT E40 Cytomegalovirus infection
A162	MEDDRA-PT-ID E40 10011831
A163	CUI E41 C1535939
A164	UMLS-Preferred-Name E41 Pneumocystis jiroveci pneumonia
A165	MEDDRA-PT E41 Pneumocystis jirovecii pneumonia
A166	MEDDRA-PT-ID E41 10073755
A167	LLT E41 Pneumocystis jiroveci pneumonia
A168	LLT-ID E41 10064108
A169	CUI E42 C1535939
A170	UMLS-Preferred-Name E42 Pneumocystis jiroveci pneumonia
A171	MEDDRA-PT E42 Pneumocystis jirovecii pneumonia
A172	MEDDRA-PT-ID E42 10073755
A173	CUI E43 C0041296
A174	UMLS-Preferred-Name E43 Tuberculosis
A175	MEDDRA-PT E43 Tuberculosis
A176	MEDDRA-PT-ID E43 10044755
A177	CUI E44 C0004364
A178	UMLS-Preferred-Name E44 Autoimmune Diseases
A179	MEDDRA-PT E44 Autoimmune disorder
A180	MEDDRA-PT-ID E44 10061664
A181	CUI E45 C0018213
A182	UMLS-Preferred-Name E45 Graves Disease
A183	MEDDRA-PT E45 Basedow's disease
A184	MEDDRA-PT-ID E45 10004161
A185	LLT E45 Graves' disease
A186	LLT-ID E45 10018706
A187	CUI E46 C0085655
A188	UMLS-Preferred-Name E46 Polymyositis
A189	MEDDRA-PT E46 Polymyositis
A190	MEDDRA-PT-ID E46 10036102
A191	CUI E47 C0018378
A192	UMLS-Preferred-Name E47 Guillain-Barre Syndrome
A193	MEDDRA-PT E47 Guillain-Barre syndrome
A194	MEDDRA-PT-ID E47 10018767
